{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:36:39Z","timestamp":1777606599770,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To describe and analyze the real-life refractive, functional and safety outcomes of the Clareon\u00ae intraocular lens (IOL) after 3 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data was collected retrospectively for observational purposes between July 2017 and December 2019 in the ophthalmology department of Desgenettes military hospital in Lyon, France. Eyes that underwent cataract surgery with Claeron\u00ae implantation were consecutively included. Patients with a systemic or ocular condition that could affect the visual outcome were excluded. Postoperative corrected (CDVA) and uncorrected (UDVA) distance visual acuities as well as capsule and IOL transparency were assessed at 1 month and 3 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 326 eyes were analyzed at one month and 191 eyes were reassessed at the 3-year follow-up visit. At 3 years, the mean CDVA was 0.003 LogMAR (95% confidence interval [CI]: -0.003 to -0.01) and the mean UDVA was 0.075 (95% CI: 0.054 to 0.095). Three quarters of the patients had an UDVA\u2009\u2265\u20090.097 logMAR (20\/25 Snellen equivalent) and 50% had an UDVA\u2009\u2265\u20090 (20\/20). The absence of glistening was reported in 95.3% of cases and 4.7% [9] of patients experienced a clinically significant posterior capsular opacification (PCO) for which Nd:YAG treatment was required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This real-life study reports high-performance and stable long-term refractive outcomes of the Clareon\u00ae IOL with good safety in terms of PCO and glistening.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-024-03393-x","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T08:06:29Z","timestamp":1711440389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term real-life outcomes of the Clareon\u00ae hydrophobic intraocular lens: the Clarte study in 191 eyes"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-5814","authenticated-orcid":false,"given":"Hugo","family":"Bouvarel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Agard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Billant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Levron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Chudzinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Plas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Sejournet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayeul","family":"Chaperon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Dot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"5","key":"3393_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","volume":"102","author":"RRA Bourne","year":"2018","unstructured":"Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol Mai. 2018;102(5):575\u201385.","journal-title":"Br J Ophthalmol Mai"},{"issue":"10","key":"3393_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jcrs.2019.05.017","volume":"45","author":"L Werner","year":"2019","unstructured":"Werner L, Thatthamla I, Ong M, Schatz H, Garcia-Gonzalez M, Gros-Otero J, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg oct. 2019;45(10):1490\u20137.","journal-title":"J Cataract Refract Surg oct"},{"issue":"10","key":"3393_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41433-018-0131-2","volume":"32","author":"PG Ursell","year":"2018","unstructured":"Ursell PG, Dhariwal M, Majirska K, Ender F, Kalson-Ray S, Venerus A, et al. Three-year incidence of nd:YAG capsulotomy and posterior capsule opacification and its relationship to monofocal acrylic IOL biomaterial: a UK Real World evidence study. Eye Oct. 2018;32(10):1579\u201389.","journal-title":"Eye Oct"},{"key":"3393_CR4","doi-asserted-by":"crossref","unstructured":"Von Tress M, Marotta J, Lane S, Sarangapani R. A meta-analysis of nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials. Clin Ophthalmol juin 2018;Volume 12:1125\u201336.","DOI":"10.2147\/OPTH.S161380"},{"issue":"3","key":"3393_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/j.jcrs.0000000000000746","volume":"48","author":"T Oshika","year":"2022","unstructured":"Oshika T, Sasaki N, Clinical Study Group on New Intraocular Lens and Delivery System. One-year multicenter evaluation of a new hydrophobic acrylic intraocular lens with hydroxyethyl methacrylate in an automated preloaded delivery system. J Cataract Refract Surg mars. 2022;48(3):275\u20139.","journal-title":"J Cataract Refract Surg mars"},{"key":"3393_CR6","doi-asserted-by":"publisher","unstructured":"Nuijts R, Bhatt U, Nanavaty MA, Roberts TV, Peterson R, Teus MA. Three-Year Multinational Clinical Study on an Aspheric Hydrophobic Acrylic Intraocular Lens. J Cataract Refract Surg [Internet]. 22 f\u00e9vr 2023 [cit\u00e9 25 mars 2023];Publish Ahead of Print. Disponible sur: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/j.jcrs.0000000000001173.","DOI":"10.1097\/j.jcrs.0000000000001173"},{"issue":"7","key":"3393_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0886-3350(02)01353-6","volume":"28","author":"D Tognetto","year":"2002","unstructured":"Tognetto D, Toto L, Sanguinetti G, Ravalico G. Glistenings in foldable intraocular lenses. J Cataract Refract Surg Juill. 2002;28(7):1211\u20136.","journal-title":"J Cataract Refract Surg Juill"},{"key":"3393_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0021-5155(01)00429-4","volume":"45","author":"A Miyata","year":"2001","unstructured":"Miyata A, Uchida N, Nakajima K, Yaguchi S. Clinical and Experimental Observation of glistening in Acrylic intraocular lenses. Jpn J Ophthalmol. 2001;45:6.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"3393_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.archger.2008.04.006","volume":"49","author":"MD Knudtson","year":"2009","unstructured":"Knudtson MD, Klein BEK, Klein R. Biomarkers of aging and falling: the Beaver dam eye study. Arch Gerontol Geriatr. 2009;49(1):22\u20136.","journal-title":"Arch Gerontol Geriatr"},{"key":"3393_CR10","doi-asserted-by":"crossref","unstructured":"Lehmann R, Maxwell A, Lubeck DM, Fong R, Walters TR, Fakadej A. Effectiveness and safety of the Clareon Monofocal intraocular Lens: outcomes from a 12-Month single-arm clinical study in a large sample. Clin Ophthalmol avr 2021;Volume 15:1647\u201357.","DOI":"10.2147\/OPTH.S295008"},{"issue":"7","key":"3393_CR11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/j.jcrs.0000000000000201","volume":"46","author":"N Stanojcic","year":"2020","unstructured":"Stanojcic N, O\u2019Brart D, Hull C, Wagh V, Azan E, Bhogal M, et al. Visual and refractive outcomes and glistenings occurrence after implantation of 2 hydrophobic acrylic aspheric monofocal IOLs. J Cataract Refract Surg Juill. 2020;46(7):986\u201394.","journal-title":"J Cataract Refract Surg Juill"},{"key":"3393_CR12","doi-asserted-by":"crossref","unstructured":"Titiyal JS, Basak SK, Shetty N, Mathur U, Padmanabhan P, Ganesh S, et al. Twelve-months Follow-Up Postmarket Study of a hydrophobic intraocular Lens using a preloaded automated injector in an Indian Population. Clin Ophthalmol. d\u00e9c 2022;16:4215\u201325.","DOI":"10.2147\/OPTH.S379054"},{"issue":"11","key":"3393_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s00347-020-01075-9","volume":"117","author":"MS Bedar","year":"2020","unstructured":"Bedar MS, Kellner U. Klinische Erfahrung Mit Der Clareon\u00ae-IOL und dem AutonoMe\u00ae-Implantationssystem. Ophthalmol Nov. 2020;117(11):1100\u20134.","journal-title":"Ophthalmol Nov"},{"issue":"5","key":"3393_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/j.jcrs.0000000000000142","volume":"46","author":"T Oshika","year":"2020","unstructured":"Oshika T, Fujita Y, Inamura M, Miyata K. Mid-term and long-term clinical assessments of a new 1-piece hydrophobic acrylic IOL with hydroxyethyl methacrylate. J Cataract Refract Surg Mai. 2020;46(5):682\u20137.","journal-title":"J Cataract Refract Surg Mai"},{"key":"3393_CR15","doi-asserted-by":"crossref","unstructured":"Maxwell A, Suryakumar R. Long-term effectiveness and safety of a three-piece acrylic hydrophobic intraocular lens modified with hydroxyethyl-methacrylate: an open-label, 3-year follow-up study. Clin Ophthalmol oct 2018;Volume 12:2031\u20137.","DOI":"10.2147\/OPTH.S175060"},{"key":"3393_CR16","unstructured":"Donachie PHJ, Sparrow JM, Buchan JC. National Ophthalmology Database Audit, Feasibility study of Post-cataract Posterior Capsule Opacification. 2021."},{"key":"3393_CR17","unstructured":"Dot C, Schweitzer C, Labbe A, Lignereux F, Rozot P, Goguillot M et al. Incidence of retinal detachment, macular edema, and ocular hypertension after nd:YAG capsulotomy: a population-based nationwide study - the FreYAG2 study. Ophthalmology. 26 d\u00e9c 2022;S0161-6420(22)01017-X."},{"key":"3393_CR18","doi-asserted-by":"crossref","unstructured":"Donachie PHJ, Barnes BL, Olaitan M, Sparrow JM, Buchan JC. The Royal College of Ophthalmologists\u2019 National Ophthalmology Database study of cataract surgery: Report 9, Risk factors for posterior capsule opacification. Eye Lond Engl. 24 ao\u00fbt. 2022.","DOI":"10.1038\/s41433-022-02204-1"},{"key":"3393_CR19","first-page":"1","volume":"2018","author":"S Wu","year":"2018","unstructured":"Wu S, Tong N, Pan L, Jiang X, Li Y, Guo M, et al. Retrospective analyses of potential risk factors for posterior Capsule Opacification after cataract surgery. J Ophthalmol 5 ao\u00fbt. 2018;2018:1\u20137.","journal-title":"J Ophthalmol 5 ao\u00fbt"},{"issue":"1","key":"3393_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40123-020-00329-8","volume":"10","author":"Q Wang","year":"2021","unstructured":"Wang Q, Yildirim TM, Schickhardt SK, \u0141abuz G, Khoramnia R, Merz PR, et al. Quantification of the in vitro predisposition to glistening formation in one manufacturer\u2019s acrylic intraocular lenses made in different decades. Ophthalmol Ther mars. 2021;10(1):165\u201374.","journal-title":"Ophthalmol Ther mars"},{"issue":"1","key":"3393_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12886-020-01349-5","volume":"20","author":"A Hillenmayer","year":"2020","unstructured":"Hillenmayer A, Wertheimer CM, Kassumeh S, von Studnitz A, Luft N, Ohlmann A, et al. Evaluation of posterior capsule opacification of the Alcon Clareon IOL vs the Alcon Acrysof IOL using a human capsular bag model. BMC Ophthalmol d\u00e9c. 2020;20(1):77.","journal-title":"BMC Ophthalmol d\u00e9c"}],"updated-by":[{"DOI":"10.1186\/s12886-024-03451-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000}}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03393-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T07:03:53Z","timestamp":1713510233000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03393-x"}},"subtitle":["3-years real-life outcomes of the Clareon\u00ae intraocular lens"],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03393-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12886-024-03451-4","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12886-024-03451-4","URL":"https:\/\/doi.org\/10.1186\/s12886-024-03451-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all the study participants. This study was approved by the Ethics Committee of the French Society of Ophthalmology (IRB 00008855).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for open access publication"}},{"value":"Corinne Dot is consultant for Abbvie, Alcon, Bayer, Horus pharma, Hoya, Novartis, Zeiss.All other authors have no disclosure to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}